Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs VanEck Gold Miners ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.02 (market cap $9.43B), while VanEck Gold Miners ETF trades at $91.52. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| BIO | GDX | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | — |
52-Week High | $356.25 | $115.84 |
52-Week Low | $241.71 | $56.60 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
GDX, the VanEck Gold Miners ETF, trades at $91.15, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF provides diversified exposure to gold mining equities amid a seven-week gold rally near $4,300 per ounce.
Outlook is positive given gold's strength, but risks include volatility from Fed policy shifts and miner underperformance versus bullion. Analyst sentiment is mixed, with some advocating for value while others caution on stretched valuations. Upside depends on sustained gold prices and mining operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
